542 Results for "

PD+L1

" in MedChemExpress (MCE) Product Catalog:
Products (542)

542 Results for "PD+L1" in MCE Product Catalog:

72
72 Publications Verification
Cat. No.: HY-16141
CAS No.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers [1] .
38
38 Cited Publications
Cat. No.: HY-P9904
CAS No.: 1380723-44-3
Synonyms: MPDL3280A; RG-7446; RO-5541267

Research Areas:  

Cancer

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
32
32 Cited Publications
Cat. No.: HY-19991
CAS No.: 1675201-83-8
Synonyms: PD-1/PD-L1 inhibitor 1
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1] .
30
30 Cited Publications
Cat. No.: HY-P9902
CAS No.: 1374853-91-4
Synonyms: MK-3475; Lambrolizumab

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
25
25 Cited Publications
Cat. No.: HY-19745
CAS No.: 1675203-84-5
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity [1] .
25
25 Cited Publications
Cat. No.: HY-19745B
CAS No.: 2089334-95-0
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity [1] .
24
24 Cited Publications
Cat. No.: HY-P99144

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma [1].
23
23 Cited Publications
Cat. No.: HY-P9903
CAS No.: 946414-94-4
Synonyms: BMS-936558; ONO-4538; MDX-1106

Target:  

PD-1/PD-L1

Research Areas:  

Infection Cancer

Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
15
15 Cited Publications
Cat. No.: HY-P99145

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer [1].
15
15 Cited Publications
Cat. No.: HY-100022
CAS No.: 1849590-01-7
Purity:  99.92%
Synonyms: eFT508
Target:  

MNK PD-1/PD-L1

Research Areas:  

Cancer

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines [1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
10
10 Cited Publications
Cat. No.: HY-108730
CAS No.: 1537032-82-8
Synonyms: Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma [1].
10
10 Cited Publications
Cat. No.: HY-108730A
CAS No.: 1537032-82-8
Purity:  96.02%

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma [1].
9
9 Cited Publications
Cat. No.: HY-P73361
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1
Species:  
Source:  
6
6 Cited Publications
Cat. No.: HY-P9919A
CAS No.: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity [1] .
6
6 Cited Publications
Cat. No.: HY-P9919
CAS No.: 1428935-60-7
Synonyms: MEDI 4736

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody [1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
6
6 Cited Publications
Cat. No.: HY-102011
CAS No.: 1818314-88-3
Purity:  99.49%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
6
6 Cited Publications
Cat. No.: HY-102011A
CAS No.: 2113650-05-6
Purity:  99.31%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
6
6 Cited Publications
Cat. No.: HY-16961
CAS No.: 1123837-84-2
Synonyms: MGCD516; MG-516
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
5
5 Cited Publications
Cat. No.: HY-P9902A
Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
4
4 Cited Publications
Cat. No.: HY-N0242
CAS No.: 28808-62-0
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 [1].